Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.

Journal of gastroenterology and hepatology - 1 Feb 2014

Matsushita Hiroshi, Ikeda Fusao, Iwasaki Yoshiaki, Seki Hiroyuki, Nanba Shintaro, Takeuchi Yasuto, Moritou Yuki, Yasunaka Tetsuya, Onishi Hideki, Miyake Yasuhiro, Takaki Akinobu, Nouso Kazuhiro, Yamamoto Kazuhide

Abstract excerpt

BACKGROUND AND AIM: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms. METHODS: The present study enrolled 228 CHC patients and assessed their HRQOLs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Forecasting
Share to Health Surveys

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Quality of Life

Share to Ribavirin

Source

Identifiers

PMID: 23869873
DOI: 10.1111/jgh.12337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.PMID 23869873Read ↗

The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.Semantic proximity Read ↗

Longitudinal Changes in Utilities and HRQoL During Interferon‑Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‑Utility AnalysisSemantic proximity Read ↗

Impact of Sofosbuvir and Daclastavir on Health-related Quality of Life in Patients Co-infected With Hepatitis C and Human Immunodeficiency VirusSemantic proximity Read ↗

Health-related quality of life and associated factors among patients with liver cancerSemantic proximity Read ↗

Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy.Semantic proximity Read ↗

The Post-Liver Transplant Quality of Life Instrument: Translation, Reliability, and Validity of the Persian VersionSemantic proximity Read ↗

Health-related quality of life in patients aged 6-18 years with chronic hepatitis C treated with sofosbuvir/velpatasvir.Semantic proximity Read ↗

Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.Semantic proximity Read ↗

Chronic heart failure health-related quality of life questionnaire (CHFQOLQ-20): Development and psychometric propertiesSemantic proximity Read ↗

Factors Associated with Health-Related Quality of Life Among Breast Cancer Survivors in the Saudi Arabia: Cross Sectional StudySemantic proximity Read ↗

Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury.Semantic proximity Read ↗

Better Health-Related Quality of Life is associated with prolonged survival and reduced hospitalization risk among Dialysis-Dependent Chronic Kidney Disease Patients: A Historical Cohort StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.